|ICD-9-CM||37.33, 37.34, 60.62|
Cryoablation is a process that uses extreme cold (cryo) to destroy or damage tissue (ablation).
Cryoablation is used in a variety of clinical applications using hollow needles (cryoprobes) through which cooled, thermally conductive, fluids are circulated. Cryoprobes are inserted into or placed adjacent to tissue which is determined to be diseased in such a way that ablation will provide correction yielding benefit to the patient. When the probes are in place, the cryogenic freezing unit removes heat ("cools") from the tip of the probe and by extension from the surrounding tissues.
Ablation occurs in tissue that has been frozen by at least three mechanisms: (1) formation of ice crystals within cells thereby disrupting membranes, and interrupting cellular metabolism among other processes; (2) coagulation of blood thereby interrupting bloodflow to the tissue in turn causing ischemia and cell death; and (3) induction of apoptosis, the so-called programmed cell death cascade.
The most common application of cryoablation is to ablate solid tumors found in the lung, liver, breast, kidney and prostate. The use in prostate and renal cryoablation are the most common. Although sometimes applied through laparoscopic or open surgical approaches, most often cryoablation is performed percutaneously (through the skin and into the target tissue containing the tumor) by a medical specialist, such as an interventional radiologist.
Prostate cryoablation is moderately effective but, as with any prostate removal process, also can result in impotence. Prostate cryoablation is used in three patient categories: (1) as primary therapy in patients for whom sexual function is less important or who are poor candidates for radical retropubic prostatectomy (RRP, surgical removal of the prostate); (2) as salvage therapy in patients who have failed brachytherapy (the use of implanted radioactive "seeds" placed within the prostate) or external beam radiation therapy (EBRT); and (3) focal therapy for smaller, discrete tumors in younger patients.
Renal cryoablation is moderately effective in smaller tumors found in the kidney and adrenal gland. In 2010, Aron, et al., presented the culmination of an 8-year study on the results of renal cryoablation and finding an overall cancer recurrence rate of 14%. Klatte, et al. (2011), and Davol, et al. (2006), also presented similar results of 11% and 13% cancer recurrence rates, respectively. Finally, as summarized by Russo(2011) via the American Society of Clinical Oncology:
"Following cryoablation, 11% of patients with RCC (Renal Cell Carcinoma - Kidney Cancer) developed local recurrence after a median duration of 14 months (range 6-18 months). In these patients, salvage nephrectomy was performed and revealed vital clear cell RCC [cancer was still present]. In contrast, there were no local or systemic recurrences following open partial nephrectomy. The 3-year recurrence-free survival probabilities following laparoscopic renal cryoablation vs. open partial nephrectomy were 83% vs. 100%, respectively (p=0.015). Perioperative complications and renal functional outcomes of laparoscopic cryoablation and open partial nephrectomy are similar; however, laparoscopic cryoablation confers a substantially higher local recurrence risk of about 15% after 3 years. Therefore, laparoscopic renal cryoablation should be reserved for high risk patients with decreased life expectancy."
Recent publications on Small Renal Masses and Renal Cryoablation can be found via: Cryoablation.org
Another type of cryoablation is used to restore normal electrical conduction by freezing tissue or heart pathways that interfere with the normal distribution of the heart’s electrical impulses. Cryoablation is used in two types of intervention for the treatment of arrhythmias: (1) catheter-based procedures and (2) surgical operations.
A catheter is a very thin tube that is inserted into a vein in the patient’s leg and threaded to the heart where it delivers energy to treat the patient’s arrhythmia. In surgical procedures, a flexible probe is used directly on an exposed heart to apply the energy that interrupts the arrhythmia. By cooling the tip of a cryoablation catheter (cardiology) or probe (heart surgery) to sub-zero temperatures, the cells in the heart responsible for conducting the arrhythmia are altered so that they no longer conduct electrical impulses.
In this FDA-approved procedure, an ultrasound-guided probe is inserted into the fibroadenoma and extremely cold temperatures are then used to destroy the abnormal cells. Over time the cells are reabsorbed into the body. The procedure can be performed in a doctor's office setting with local anesthesia and leaves very little scarring compared to open surgical procedures.
Different catheter-based ablation techniques may be used and they generally fall into two categories: (1) cold-based procedures where tissue cooling is used to treat the arrhythmia, and (2) heat-based procedures where high temperature is used to alter the abnormal conductive tissue in the heart.
Cold temperatures are used in cryoablation to chill or freeze cells that conduct abnormal heart rhythms. The catheter removes heat from the tissue to cool it to temperatures as low as -75°C. This causes localized scarring, which cuts undesired conduction paths.
This is a much newer treatment for supraventricular tachycardia (SVT) involving the atrioventicular (AV) node directly. SVT involving the AV node is often a contraindication for using radiofrequency ablation because of the risk of injuring the AV node, forcing patients to receive a permanent pacemaker. With cryoablation, areas of tissue can be mapped by limited, reversible, freezing (e.g. to -10 C). If the result is undesirable, the tissue can be rewarmed without permanent damage. Otherwise, the tissue can be permanently ablated by freezing it to a lower temperature (e.g. -73 C).
This therapy has revolutionized AV nodal reentrant tachycardia (AVNRT) and other AV nodal tachyarrhythmias. It has allowed people who were otherwise not a candidate for radiofrequency ablation to have a chance at having their problem cured. This technology was pioneered at The Montreal Heart institute in the late 1990s. The therapy was successfully adopted in Europe in 2001, and in the USA in 2004 following the "Frosty Trial". </ref>
Cryoablation for AVNRT and other arrhythmias do have some drawbacks. A recent study concluded that procedure times are slightly higher on average for cryoablation than for traditional Radio-Frequency (heat-based) ablations. Also, higher rate of equipment failures were recorded using this technique. Finally, even though short term success rate is equivalent to RF treatments, Cryoablation appears to have a significantly higher long term recurrence rate.
Cryotherapy is able to produce a temporary electrical block by cooling down the tissue believed to be conducting the arrhythmia. This allows the physician to make sure this is the right site before permanently disabling it. The ability to test a site in this way is referred to as site testing or cryomapping.
When ablating tissue near the AV node (a special conduction center that carries electrical impulses from the atria to the ventricles), there is a risk of producing heart block - that is, normal conduction from the atria cannot be transmitted to the ventricles. Freezing tissue near the AV node is less likely to provoke irreversible heart block than ablating it with heat.
As in catheter-based procedures, techniques using heating or cooling temperatures may be used to treat arrhythmias during heart surgery. Techniques also exist where incisions are used in the open heart to interrupt abnormal electrical conduction (Maze procedure). Cryosurgery involves the use of freezing techniques for the treatment of arrhythmias during surgery.
A physician may recommend cryosurgery being used during the course of heart surgery as a secondary procedure to treat any arrhythmia that was present or that may appear during the primary openchest procedure. The most common heart operations in which cryosurgery may be used in this way are mitral valve repairs and coronary artery bypass grafting. During the procedure, a flexible cryoprobe is placed on or around the heart and delivers cold energy that disables tissue responsible for conducting the arrhythmia.
- General references
- Liapi E, Geschwind JF. J Clin Oncol. Transcatheter and ablative therapeutic approaches for solid malignancies. 2007 Mar 10;25(8):978-86.
- Rukstalis, D and KatzHandbook, A Handbook of Urologic Cryoablation, hardcover - Feb 13, 2007.
- Jensen-Urstad, et al., Cryoablation of AV Nodal Reentrytachycardia, PACE, Vol. 29 May 2006, pp 487.
- Doll, et al., Intraoperative Cryoablation with a new Argon Probe, Ann Thorac Surg 2004;77:1460–2.
- Inline citations
- Aron, M., K. Kamoi, E. Remer, A. Berger, M. Desai, and I. Gill. “Laparoscopic renal cryoablation: 8-year, single surgeon outcomes.” The Journal of urology 183, no. 3 (2010): 889–895
- Klatte, T., Mauermann, M. Waldert, Heinz-Peer, P. Weibl, H.C. Klingler, and M. Remzi. “Perioperative oncological and functional outcomes of laparoscopic renal cryo-ablation and open partial nephrectomy: A matched pair analysis.” European Urology Supplements 10, no. 2 (2011): 110.
- Davol, P. E, B. R Fulmer, and D. B Rukstalis. “Long-term results of cryoablation for renal cancer and complex renal masses.” Urology 68, no. 1 (2006): 2–6.
- Russo, Paul. “Shifting sands in the clinical management of T1 renal mass.” American Society of Clinical Oncology, 2011. http://www.asco.org/ASCOv2/Meetings/Genitourinary+Cancers+Symposium/2011+Genitourinary+Cancers+Symposium+Daily+News/Features/Expert+Editorial:+Shifting+Sands+in+the+Clinical+Management+of+the+T1+Renal+Mass.
- Medical Dictionary
- WebMD - Cryotherapy Shrinks Benign Breast Lumps
- Nov. 2010 German CYRANO study (Cryoablation Versus Radiofrequency Energy for the Ablation of Atrioventricular Nodal Reentrant Tachycardia)